Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL

Abstract The predictors of hepatitis B virus (HBV) relapse and HBsAg loss after cessation of nucleos(t)ide analogues (NA) in HBeAg-negative patients with end-of-treatment HBsAg ≤ 200 IU/mL remains unclear. The study recruited 119 chronic hepatitis B (CHB) patients who achieved end-of-treatment HBsAg...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chih-Chien Yao, Chao-Hung Hung, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Hung Wang, Chung-Mo Lee, Chien-Hung Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e9d7f4cc71a24678ab25493d5efa1b2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9d7f4cc71a24678ab25493d5efa1b2b
record_format	dspace
spelling	oai:doaj.org-article:e9d7f4cc71a24678ab25493d5efa1b2b2021-12-02T15:05:50ZIncidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL10.1038/s41598-017-02010-w2045-2322https://doaj.org/article/e9d7f4cc71a24678ab25493d5efa1b2b2017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02010-whttps://doaj.org/toc/2045-2322Abstract The predictors of hepatitis B virus (HBV) relapse and HBsAg loss after cessation of nucleos(t)ide analogues (NA) in HBeAg-negative patients with end-of-treatment HBsAg ≤ 200 IU/mL remains unclear. The study recruited 119 chronic hepatitis B (CHB) patients who achieved end-of-treatment HBsAg ≤ 200 IU/mL, were treated with lamivudine (n = 34) and entecavir (n = 85). The 5-year rates of post-treatment virological relapse, clinical relapse, and HBsAg loss at 60 months were 39.4%, 27.6%, and 45.9%, respectively. Cox regression analysis revealed that HBV DNA at entry and end-of-treatment HBsAg levels were independent predictors of virolgical and clinical relapse. HBV genotype C and end-of-treatment HBsAg were independent factors of HBsAg loss. Patients with a combination of end-of-treatment HBsAg < 50 IU/mL and HBV DNA < 2 × 105 IU/mL at entry experienced the lowest virological and clinical relapse rates (5% and 0% at 60 months, respectively). In contract, patients with a combination of end-of-treatment HBsAg ≥ 50 IU/mL and HBV DNA ≥ 2 × 105 IU/mL at entry experienced high virological and clinical relapse (80.7% and 71.5% at 60 months, respectively). No patients experienced hepatic decompensation when clinical relapse occurred after timely retreatment. A combination of HBV DNA levels at entry and end-of-treatment HBsAg levels was useful for predicting the post-treatment HBV relapse in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.Chih-Chien YaoChao-Hung HungTsung-Hui HuSheng-Nan LuJing-Hung WangChung-Mo LeeChien-Hung ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chih-Chien Yao Chao-Hung Hung Tsung-Hui Hu Sheng-Nan Lu Jing-Hung Wang Chung-Mo Lee Chien-Hung Chen Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
description	Abstract The predictors of hepatitis B virus (HBV) relapse and HBsAg loss after cessation of nucleos(t)ide analogues (NA) in HBeAg-negative patients with end-of-treatment HBsAg ≤ 200 IU/mL remains unclear. The study recruited 119 chronic hepatitis B (CHB) patients who achieved end-of-treatment HBsAg ≤ 200 IU/mL, were treated with lamivudine (n = 34) and entecavir (n = 85). The 5-year rates of post-treatment virological relapse, clinical relapse, and HBsAg loss at 60 months were 39.4%, 27.6%, and 45.9%, respectively. Cox regression analysis revealed that HBV DNA at entry and end-of-treatment HBsAg levels were independent predictors of virolgical and clinical relapse. HBV genotype C and end-of-treatment HBsAg were independent factors of HBsAg loss. Patients with a combination of end-of-treatment HBsAg < 50 IU/mL and HBV DNA < 2 × 105 IU/mL at entry experienced the lowest virological and clinical relapse rates (5% and 0% at 60 months, respectively). In contract, patients with a combination of end-of-treatment HBsAg ≥ 50 IU/mL and HBV DNA ≥ 2 × 105 IU/mL at entry experienced high virological and clinical relapse (80.7% and 71.5% at 60 months, respectively). No patients experienced hepatic decompensation when clinical relapse occurred after timely retreatment. A combination of HBV DNA levels at entry and end-of-treatment HBsAg levels was useful for predicting the post-treatment HBV relapse in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.
format	article
author	Chih-Chien Yao Chao-Hung Hung Tsung-Hui Hu Sheng-Nan Lu Jing-Hung Wang Chung-Mo Lee Chien-Hung Chen
author_facet	Chih-Chien Yao Chao-Hung Hung Tsung-Hui Hu Sheng-Nan Lu Jing-Hung Wang Chung-Mo Lee Chien-Hung Chen
author_sort	Chih-Chien Yao
title	Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
title_short	Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
title_full	Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
title_fullStr	Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
title_full_unstemmed	Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
title_sort	incidence and predictors of hbv relapse after cessation of nucleoside analogues in hbeag-negative patients with hbsag ≤ 200 iu/ml
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e9d7f4cc71a24678ab25493d5efa1b2b
work_keys_str_mv	AT chihchienyao incidenceandpredictorsofhbvrelapseaftercessationofnucleosideanaloguesinhbeagnegativepatientswithhbsag200iuml AT chaohunghung incidenceandpredictorsofhbvrelapseaftercessationofnucleosideanaloguesinhbeagnegativepatientswithhbsag200iuml AT tsunghuihu incidenceandpredictorsofhbvrelapseaftercessationofnucleosideanaloguesinhbeagnegativepatientswithhbsag200iuml AT shengnanlu incidenceandpredictorsofhbvrelapseaftercessationofnucleosideanaloguesinhbeagnegativepatientswithhbsag200iuml AT jinghungwang incidenceandpredictorsofhbvrelapseaftercessationofnucleosideanaloguesinhbeagnegativepatientswithhbsag200iuml AT chungmolee incidenceandpredictorsofhbvrelapseaftercessationofnucleosideanaloguesinhbeagnegativepatientswithhbsag200iuml AT chienhungchen incidenceandpredictorsofhbvrelapseaftercessationofnucleosideanaloguesinhbeagnegativepatientswithhbsag200iuml
_version_	1718388678194102272

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL

Ejemplares similares